Is It Policy And Not Treatment That Actually Determines Epilepsy Outcomes?

Abstract

Epilepsy is among the most prevalent and treatable neurological disorders worldwide, yet it remains associated with persistent and preventable inequities in morbidity and mortality. Despite major advances in diagnostics, pharmacotherapy, and surgery, substantial treatment gaps and excess mortality persist globally across all income segments of society. These outcomes frequently reflect failures of access, continuity, and health-system design, rather than limitations of existing therapies. Using epilepsy specifically as a tracer neurological condition, this analysis examines how health systems respond to chronic neurological disease under stress. In many low- and middle-income countries and other underserved settings, health systems have evolved passively, shaped by fragmented financing, short-term priorities, and misaligned incentives rather than by intentional, outcome-oriented policy. Evidence from global neurology and health economics shows that such passive system development produces reactive care models, inefficient resource use, and high indirect costs due to productivity loss, caregiver burden, injury, disability, and premature mortality. Environmental and climate-related stressors further expose these structural weaknesses in vulnerable regions. Extreme weather events, environmental instability, and displacement disrupt medication supply, infrastructure, and continuity of neurological care. In epilepsy, even brief interruptions in treatment can precipitate breakthrough seizures, injury, or death, transforming environmental exposure into avoidable neurological harm. This article contends that policy is the primary determinant of whether health systems remain reactive or become resilient. Secondly, we propose that artificial intelligence (AI) may play a critical enabling role by supporting the development of context-appropriate policy and system design. When aligned with local realities, AI-facilitated policy could enable earlier diagnosis, sustained treatment, and more efficient resource allocation. Proactive epilepsy care is therefore not only an ethical imperative but an economically rational strategy. Aligning policy, technology, and health system design is essential to deliver durable, equitable, and cost-effective epilepsy care in an era of accelerating environmental and geopolitical change where external funding is diminishing globally.

Background and Global Context

Neurological disorders are now increasingly recognized as a leading cause of disability worldwide, yet neurology has historically remained underprioritized within global health policy and financing frameworks.^1,2 Epilepsy, affecting tens of millions of people globally and steadily increasing in prevalence as the global population ages, exemplifies this paradox. It is common, chronic, and in most cases highly treatable, yet outcomes remain deeply inequitable and stagnant across and within countries.^3–5 Treatment gaps exceeding 70% persist in many low- and middle-income settings and are also observed among marginalized populations in high-income countries. ³

Over recent decades, the clinical landscape of epilepsy has been transformed by advances in antiseizure medications, neurodiagnostics, digital technologies, and surgical therapies. ⁶ However, these innovations have not translated into commensurate improvements in equity, access, or sustainability. ⁷ This disconnect highlights the central position of this paper: that financial and policy structures, rather than scientific and clinical capability, are the dominant determinants of epilepsy outcomes.

Epilepsy is a chronic, life-threatening, disease requiring daily treatment that can be lifelong and reactive to external and internal fluctuations, with different people with epilepsy having distinct specific needs. Additionally, effective treatment often depends on developing a meaningful rapport between a provider and the patient, especially in longstanding epilepsy care. Therefore, epilepsy reveals how weaknesses in underlying financing, workforce planning, relevant insurance architecture, and systems resilience can influence chronic care.

Used deliberately as a tracer condition, epilepsy allows examination of how health-system design choices shape long-term neurological outcomes under conditions of resource constraint and environmental stress. Indeed, elevated mortality in people with epilepsy, including sudden unexpected death in epilepsy and seizure-related injuries, has been linked not only to biological risk but also to failures of awareness, access, continuity, and system design, rather than solely to a lack of effective therapies as is usually emphasized. ⁸ To facilitate a deeper understanding, we explore how disparities in epilepsy outcomes are due to inadequacies and variation in financial structures, workforce and access, as well as their downstream negative consequences and implications.

Financial Gaps as Structural Misalignment

Taken together, financial gaps—and their downstream consequences—reflect health systems that have evolved largely passively, responding to immediate pressures rather than being intentionally designed by suitable policy to optimize long-term neurological outcomes. In epilepsy care, monetary gaps are frequently interpreted as simple shortages of funding. In actuality, gaps arise from systemic misalignment across policy prioritization, resource allocation and health investment incentives—gaps that can exist even in health systems with substantial overall expenditure.^5,9

Recognizing that countries exist on a spectrum of resources and policy sophistication, each country and region will have their own unique weighting of these issues. ¹⁰ Policy signals determine which conditions are prioritized, monitored, and financed. Conditions not explicitly named within national strategies rarely receive protected budgets. Epilepsy, a highly stigmatized condition in many poorer countries, is exemplary of this. It is for this reason the World Health Organization's (WHO) Intersectoral Global Action Plan was created. ⁹

Resource allocation mechanisms further entrench inequity by privileging acute, episodic, and hospital-based care over longitudinal, community-based management of chronic neurological disorders. Epilepsy care, requiring sustained outpatient followup, diagnostic services, and uninterrupted medication supply, fits poorly within funding models designed around short episodes of care. As a result, epilepsy services are often concentrated in tertiary centers, increasing geographic and socioeconomic barriers to access.^9,10

Health investment behavior reinforces these negative patterns. Health economics and outcomes research in low- and middle-income countries suggests that disruptive technologies, including AI and digital tools, may exacerbate inequities if financing and governance structures are not aligned to value, access, and sustainability.^10–12

Workforce, Insurance, and Access

Workforce capacity, insurance architecture, and access pathways are often treated as downstream operational concerns. In practice, they function as core financial and policy structures that determine whether epilepsy care can be delivered effectively and equitably. Weaknesses in any of these domains produce fragmentation that disproportionately penalizes relatively low-volume, high-complexity specialties such as epilepsy, often resulting in high out-of-pocket costs and delayed care. The WHO's Neurology Atlas documents profound global variation in neurology workforce density, with many low- and middle-income countries reporting severe shortages of both adult and pediatric neurologists. ² In such settings, limited specialist capacity contributes directly to diagnostic delay, prolonged treatment gaps, and preventable morbidity beginning in childhood. These shortages reflect not only training limitations but also longstanding policy choices regarding specialist posts, career pathways, and retention incentives.

In higher-income settings, workforce challenges are less about absolute scarcity and more about maldistribution, sustainability, and burnout. Population ageing—a global phenomenon, not confined to high income settings—and the rising burden of neurological disease have increased demand, while administrative burden and productivity pressures have eroded effective clinical capacity.^13,14

In countries without universal healthcare models, insurance design interacts with workforce constraints to shape access. In fragmented insurance environments, such as the United States, reimbursement structures often undervalue chronic neurological care, longitudinal followup, and care coordination. Telemedicine is an example of technological advancement in healthcare delivery that can overcome social and geographic barriers and yet is heavily regulated and not permanently integrated into most healthcare systems.^15,16 This fragmentation penalizes relatively low-volume high-complexity specialties like epilepsy care in particular, producing high out-of-pocket costs for many. Prior authorization requirements (particularly needed for newer and safer medications), restrictive formularies, and unstable coverage with superfluous hurdles disrupts continuity of care, subsequently increasing seizure risk, gaps in medication compliance, and avoidable emergency utilization. ¹⁴

In low-resource settings around the world, limited and often nonexistent insurance coverage shifts costs directly to households through out-of-pocket payment, contributing to treatment interruption due to lack of household funds (also limiting access to newer and safer medications).^17,18 This can lead to catastrophic expenditure or suboptimal evaluations and treatments. In addition, access barriers extend beyond financing and insurance. Geographic concentration of services and indirect costs such as travel and lost wages further constrain utilization, particularly for rural and marginalized populations. These constraints reinforce inequities and undermine the eventual effectiveness of evidence-based interventions, even when therapies are nominally available.^19–21

Economic Consequences of Policy Inaction

The economic burden of epilepsy extends far beyond direct healthcare expenditure, yet this broader cost profile remains systematically under-appreciated. While the costs of antiseizure medications, diagnostic investigations, and specialist consultations are often subject to scrutiny, these represent only a fraction of the total economic impact of epilepsy when viewed from a societal perspective. Inadequate governmental investment in sustained epilepsy care therefore does not reduce costs; instead, it displaces them to households, employers, and other sectors of society.^22–25 Poor seizure control is consistently associated with reduced educational attainment, lower employment participation, increased caregiver burden, higher risk of injury and disability, reduced quality of life, and premature mortality.^21–23,25 These consequences generate recurrent and long-term economic losses through reduced productivity, informal caregiving, social exclusion, and welfare dependency. In many settings, these indirect and systemic costs exceed the direct costs of care delivery, yet they remain largely invisible within health budgets and policy evaluations. ²⁴ Indeed, from a societal perspective, these indirect and systemic costs frequently exceed the direct costs of care delivery.^26,27

From a health system perspective, underinvestment in outpatient care and medication continuity leads to inefficient patterns of service utilization. Limited access to sustained ambulatory management increases reliance on emergency services and inpatient admissions, forms of care that are substantially more expensive and deliver inferior long-term outcomes. This dynamic represents a classic false economy, in which short-term cost containment generates higher downstream expenditure while worsening clinical outcomes.

These inefficiencies are particularly pronounced in health systems that have evolved passively, without deliberate alignment between financing mechanisms, service delivery models, and long-term outcome goals. In both low-resource settings and fragmented high-income systems, reliance on crisis-driven care reflects policy and insurance architectures that prioritize episodic acute interventions over chronic disease management.

When productivity loss, preventable injury, and premature mortality are incorporated into economic assessment, the rationale for sustained investment becomes much clearer. Prevention, early diagnosis, and durable seizure control are thus not only ethical imperatives but become economically rational, and generally cost-saving, strategies.^26,27 Framing epilepsy care through this broader more comprehensive economic lens highlights the opportunity cost of policy inaction and, in our opinion, underscores the essential role of policy in determining whether health systems generate long-term value, measured in both cost-effectiveness and outcomes, or just perpetuate avoidable inefficiencies.

In summary, in all healthcare systems, prevention with early diagnosis, optimal individualized treatment, and sustained seizure control are economically rational cost-saving strategies.^28,29

Final Implications

Closing pecuniary gaps in epilepsy care, as in other chronic disorders, requires coordinated, system-level reform. In settings dependent on insurance, expanding insurance coverage without parallel workforce investment risks amplifying unmet demand, while training specialists without addressing reimbursement, retention, and working conditions perpetuates maldistribution—and the constant threat of brain-drain to greener pastures. Policy, fiscal allocation, and health system investment must therefore be carefully aligned to long-term value generation including measurable outcomes, consistent with the WHO Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders.^9,30,31

From a technological perspective, recognizing that budgetary outlays are often focused on technological acquisitions, digital health, and outcome measures can better support more efficient epilepsy care in low-resourced environments when embedded within reimbursement and governance frameworks rather than deployed as stand-alone solutions.^11,12,32

Climate change further exposes system fragility. Extreme weather events stress-test health systems, disrupting infrastructure and medication supply chains. Any interruption of antiseizure medication access can precipitate seizures and emergencies. Emerging work on climate resilience in epilepsy care underscores the importance of integrating chronic neurological conditions into climate-health adaptation and financing strategies. ³³ Climate resilience must be incorporated into health policy as a matter of chronic disease continuity, not solely disaster preparedness, noting that the countries most vulnerable to climate change are often those with the least resources to address its consequences. ³⁴

Finally, trust operates as a systems enabler with direct economic consequences. Effective policy implementation depends on governance structures that foster trust and accountability. Reliable and appropriate medication supply, transparent and fair coverage decisions, and stable care pathways reduce transaction costs, support adherence, and provide safer care. This will increase the return on investment in epilepsy care, whether governmental, private sector or philanthropic investment, the latter two of which are greatly dependent on trust in governmental institutions.

Conclusions

Persistent gaps in epilepsy outcomes in many under resourced environments may fundamentally reflect chronic structural misalignment across health financing and policy prioritization rather than scientific and resource limitations as traditionally tends to be the focus. Viewed through the lens of epilepsy as a tracer condition, these misalignments illustrate how passively evolved, reactive systems have consistently failed to translate clinical advances into durable population-level benefit. Epilepsy vividly illustrates how a common, treatable chronic condition can remain neglected across varying healthcare systems when lack of policy prioritization, and therefore financing frameworks, cause lost opportunities for creating long-term health and societal economic value.

While policy creates the setting for optimizing financial frameworks and alignments, it is often the case in many under-resourced environments that limited available human capacity delays or constrains policy formulation. This may lead to misallocated financing and service models that are poorly aligned with local epidemiology, infrastructure, and environmental risk. Thus, in many settings, policy development lags behind needs. AI, in being able to integrate multiple streams of data to synthesize coherent context-relevant policy, may prove a valuable tool for expediting appropriate health policy and institutional reform in these settings, potentially finally breaking this cycle of economic inefficiencies and weak policy.^12,35 Carefully used in this way, AI functions not as a substitute for governance, but potentially as an accelerator of policy capacity, enabling health systems to shift from reactive crisis response toward proactive, value-oriented neurological care.

Epilepsy and its care, as a tracer condition, should be explicitly included in national climate-health adaptation plans, with dedicated financing for medication continuity, decentralized service delivery, and procurement during disruptions. Failure to integrate climate resilience into epilepsy policy risks repeated loss of gains following climate events, particularly in vulnerable regions.

From a policy standpoint, resilience financing actually represents risk mitigation, protecting prior investment in health systems and human capital. The climate crisis, if properly framed like issues of national security, may well prove to be a unifying issue that can garner sustained consensus of commitment, even through changes in governments.

Epilepsy has no borders. ⁷ It is a disease affecting people of all ages and backgrounds, and for a multitude of reasons. It may now be appropriate to reframe the care of epilepsy as an ethical and economic imperative and in this way create pathways to better rates of seizure freedom and lesser seizure burden. Framing policy and financing around long-term outcomes offers the opportunity not only to improve epilepsy care, but to strengthen all health systems, in pursuit of the obtainable goal: equitable and sustainable population health.